Spots Global Cancer Trial Database for Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis

Official Title: TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile

Study ID: NCT00432406

Conditions

Psoriatic Arthritis

Interventions

Infliximab

Etanercept

Study Description

Brief Summary: The purpose of this study is: * To elucidate the immunomodulating properties of anti-TNF-α therapy in patients with psoriatic arthritis (PsA). * To ascertain whether magnetic resonance imaging (MRI) is a sensitive tool in measuring early response after therapy with anti-TNF-α in the PsA wrist using the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) guidelines for rheumatoid arthritis (RA). * To assess whether the lipid and other cardiovascular risk profiles would improve after anti-TNF-α therapy in patients with PsA.

Detailed Description: The study was a 12-week, open-label trial of anti-TNF therapy in 20 consecutive patients (Group 1). Another 20 consecutive patients with active disease whom have met the exclusion criteria, or were unwilling to start anti-TNF therapy for fear of toxicity would be recruited as control patients (Group 2). 20 healthy controls were recruited for comparison of the metabolic risk factors (Group 3). Study visits for groups 1 and 2 were conducted at baseline, weeks 2 and 6, and then week 12.